【摘要】 目的 探讨类风湿关节炎(rheumatoid arthritis,RA)使用甲氨蝶呤片联合艾拉莫德治疗的临床效果。方法 选取2022年7月—2024年7月在无锡市第二人民医院风湿免疫科接受治疗的60例RA患者为研究对象,根据治疗药物的不同进行分组。30例接受甲氨蝶呤治疗的患者设为对照组;30例接受甲氨蝶呤联合艾拉莫德治疗的患者设观察组,2组均治疗3个月。比较治疗后2组的临床疗效、炎症因子水平、症状改善及不良反应发生情况。结果 治疗3个月后,观察组总有效率高于对照组(93.33%vs. 70.00%),差异有统计学意义(P<0.05)。观察组的C反应蛋白(C-reactive protein,CRP)、血清淀粉样蛋白A(serum amyloid A,SAA)、红细胞沉降率(erythrocyte sedimentation rate,ESR)水平及视觉模拟评分法(visual analogue sacle,VAS)评分分别为(11.52±1.35)mg/L、(24.50±2.01)mg/L、(15.25±2.41)mm/h、(3.00±0.21)分,低于对照组的(17.95±4.75)mg/L、(75.71±3.69)mg/L、(31.75±5.61)mm/h、(4.09±0.34)分,差异均有统计学意义(P<0.05)。观察组的晨僵时间为(36.03±5.14)min,短于对照组的(69.25±8.25)min,差异有统计学意义(P<0.05)。2组不良反应总发生率比较,差异无统计学意义(P > 0.05)。结论 采用甲氨蝶呤片联合艾拉莫德治疗RA,临床效果好,可有效减轻炎症反应,改善临床症状,且不增加不良反应发生风险。更多还原

【Abstract】 Objective To investigate the clinical efficacy of methotrexate tablets combined with lguratimod in the treatment of rheumatoid arthritis(RA). Methods Sixty patients with RA who received treatment in the rheumatology and immunology department of Wuxi Second People’s Hospital from July 2022 to July 2024 were selected as the study subjects. The patients were divided into groups based on treatment regimens. Thirty patients treated with methotrexate were assigned to the control group, while 30 patients treated with methotrexate combined with lguratimod were assigned to the observation group. Both groups underwent treatment for three months. The clinical efficacy, inflammatory factor levels, symptom improvement, and incidence of adverse reactions were compared between the two groups after treatment. Results After 3 months of treatment, the total effective rate of the observation group was higher than that of the control group(93.33% vs. 70.00%), and the difference was statistically significant(P < 0.05). The levels of C-reactive protein(CRP), serum amyloid A(SAA), erythrocyte sedimentation rate(ESR), and visual analog scale(VAS) scores in the observation group were(11.52±1.35) mg/L,(24.50±2.01) mg/L,(15.25±2.41) mm/h, and(3.00±0.21) points, respectively, which were lower than those in the control group, which were(17.95±4.75) mg/L,(75.71±3.69) mg/L,(31.75±5.61) mm/h, and(4.09±0.34) points, with significant differences, and the differences were statistically significant(P < 0.05). The morning stiffness time of the observation group was(36.03±5.14) minutes, which was shorter than(69.25±8.25) minutes of the control group, and the difference was statistically significant(P < 0.05). There was no statistically significant difference in the overall incidence of adverse reactions between the two groups(P > 0.05). Conclusion The use of methotrexate tablets combined with lguratimod in the treatment of RA has shown good clinical efficacy, effectively reducing inflammatory reactions, improving clinical symptoms, and not increasing the risk of adverse reactions.更多还原